A Phase 1 Study Of Pf-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (Nhl)
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Utomilumab (Primary) ; Rituximab
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 12 Dec 2017 Planned End Date changed from 5 Nov 2019 to 1 Jan 2020.
- 12 Dec 2017 Planned primary completion date changed from 6 Sep 2019 to 1 Nov 2019.
- 28 Sep 2017 Planned End Date changed from 1 Nov 2019 to 5 Nov 2019.